Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients

Multiple Sclerosis Journal

Volumn 19, Issue 11, 2013, Pages 1443-1453

  Martino, Sabata ^a   Montesano, Simona ^a   Di Girolamo, Ilaria ^a   Tiribuzi, Roberto ^a   Di Gregorio, Maria ^a,b   Orlacchio, Antonio ^b,c   Datti, Alessandro ^a,d   Calabresi, Paolo ^a,b   Sarchielli, Paola ^a   Orlacchio, Aldo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

cathepsins; diagnosis; multiple sclerosis; stem cell

Indexed keywords

BETA1A INTERFERON; CATHEPSIN D; CATHEPSIN S; CD34 ANTIGEN; INTERLEUKIN 16; PROTEIN PRECURSOR;

ADULT; ARTICLE; CELL MATURATION; CELL POPULATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CATHEPSINS; DIAGNOSIS; MULTIPLE SCLEROSIS; STEM CELL;

ADULT; ANTIGENS, CD34; CATHEPSIN D; CATHEPSINS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84884574670     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513477230     Document Type: Article

References (30)

1. Stadelmann C. Multiple sclerosis as a neurodegenerative disease: Pathology, mechanisms and therapeutic implications. Curr Opin Neurol. 2011 ; 24: 224-229
2. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006 ; 354: 942-945
3. Kieseier BC, Stüve O. A critical appraisal of treatment decisions in multiple sclerosis - old versus new. Nat Rev Neurol. 2011 ; 7: 255-262
4. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010 ; 120: 3421-3431
5. Delamarre L, Pack M, Chang H. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 2005 ; 307: 1630-1634
6. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol. 2003 ; 3: 472-482
7. Nagai A, Murakawa Y, Terashima M, et al. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurol. 2000 ; 55: 1828-1832
8. Bever CT, Garver DW. Increased cathepsin B activity in multiple sclerosis brain. J Neurol Sci. 1995 ; 131: 71-73
9. Haves-Zburof D, Paperna T, Gour-Lavie A, et al. Cathepsins and their endogenous inhibitors cystatins: Expression and modulation in multiple sclerosis. J Cell Mol Med. 2011 ; 15: 2421-2429
10. Staun-Ram E, Miller A. Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: Modulation by interferon-β and role played in cell migration. J Neuroimmunol. 2011 ; 232: 200-206
11. Clark AK, Malcangio M. Microglial signalling mechanisms: Cathepsin S and Fractalkine. Exp Neurol. 2012 ; 234: 283-292
12. Muraro PA, Vergelli M, Kalbus M. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. J Clin Invest. 1997 ; 100: 339-349
13. Beck H, Schwarz G, Schröter CJ, et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol. 2001 ; 31: 3726-3736
14. Pritzker LB, Joshi S, Gowan JJ, et al. Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry. 2000 ; 39: 5374-5381
15. Ma J, Tanaka KF, Yamada G, et al. Induced expression of cathepsins and cystatin C in a murine model of demyelination. Neurochem Res. 2007 ; 32: 311-320
16. Baugh M, Black D, Westwood P, et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun. 2011 ; 36: 201-209
17. Martino S, Tiribuzi R, Ciraci E, et al. Coordinated involvement of cathepsins S, D and cystatin C in the commitment of hematopoietic stem cells to dendritic cells. Int J Biochem Cell Biol. 2011 ; 43: 775-778
18. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121
19. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: Revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
21. Tiribuzi R, Martino S, Ciraci E, et al. Non-redundant roles of cathepsins L, B and S in CD1a+ dendritic cells knocked-down for cathepsin S by RNA interference. Minerva Biotecnol. 2008 ; 20: 59-67
22. Chen YC, Chen SD, Miao L, et al. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol. 2012 ; 243: 56-60
23. Kitamura H, Kamon H, Sawa S, et al. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity. 2005 ; 23: 491-502
24. Della Bella S, Nicola S, Timofeeva I, et al. Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells?. Blood. 2004 ; 104: 4020-4028
25. Vrethem M, Kvarnstrom M, Stenstam J, et al. Cytokine mapping in cerebrospinal fluid and blood in multiple sclerosis patients without oligoclonal bands. Mult Scler. 2012 ; 18: 669-673
26. Nicoletti F, Di Marco R, Patti F, et al. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha. Cytokine. 2000 ; 12: 682-687
27. Skundric DS, Zhou W, Cruikshank WW, et al. Increased levels of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J Autoimmun. 2005 ; 25: 206-214
28. Skundric DS, Cai J, Cruikshank WW, et al. Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflamm. 2006 ; 26: 3-13
29. Kürtüncü M, Tüzün E, Türkoǧlu R, et al. Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23. Cytokine. 2012 ; 59: 400-402
30. Gupta S, Singh RK, Dastidar S, et al. Cysteine cathepsin S as an immunomodulatory target: Present and future trends. Expert Opin Ther Targets. 2008 ; 12: 291-299